Photo Credit: Liubomyr
The following is a summary of “Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids,” published in the October 2024 issue of Allergy and Immunology by Yao et al.
Leukotriene-receptor antagonists (LTRA) and inhaled corticosteroids (ICS) are common asthma medications. Few studies investigate their comparative risks for neuropsychiatric adverse events (NAEs).
Researchers conducted a retrospective study to investigate the comparative risks of LTRA vs ICS on 7 categories of NAEs in patients with asthma nationwide.
They conducted a nationwide cohort study from 2010 to 2021, assessing incident NAEs and their subgroups. Cox proportional hazards regressions quantified the comparative risks.
The results showed that among 1,249,897 patients with asthma aged 6 to 64 years, incidence rates for NAEs were 25.10 per 1,000 person-years for those treated with ICS, yielding an incidence rate difference of 1.64 [95% CI: 0.30-2.98] per 1,000 person-years. Positive associations for NAEs and 3 clinical subgroups were observed in LTRA-treated patients compared to ICS (HR): 1.06 [95% CI: 1.00-1.12] for NAEs; HR: 1.88 [95% CI: 1.24-2.84] for psychotic disorders; HR: 1.10 [95% CI: 1.01-1.20] for anxiety disorders; HR: 1.27 [95% CI: 1.02-1.58] for behavioral and emotional disorders), but not for movement, mood, sleep-related, or personality disorders.
Investigators concluded that asthma patients treated with LTRA had higher risks of NAEs compared to those on ICS. This highlighted the need for clinicians to discuss these risks with patients when prescribing LTRA.
Source: jaci-inpractice.org/article/S2213-2198(24)00955-3/fulltext
